Nigel J. Clarke received his Ph.D. in mass spectrometry and analytical chemistry from the University of Kent, England, and completed postdoctoral fellowship training in biomedical mass spectrometry at the Mayo Clinic. He was principal investigator at the Schering-Plough Research Institute in Kenilworth NJ, running the drug discovery metabolite identification group and worked at ActivX Biosciences as director of mass spectrometry before joining Quest Diagnostics.
Dr. Clarke is chief scientific officer and vice president for R&D – clinical solutions and technology overseeing R&D groups developing LC-MS/MS, infectious disease and immunology assays utilized across Quest Diagnostics. His staff trains visiting scientists from other Quest Diagnostics labs in adopting new technology and assays from his laboratory. He oversees the running of LCMS assays across multiple operations laboratories within the Quest network.